- Home
- RCUS vs LILAK Comparison
RCUS vs LILAK Comparison
Compare RCUS & LILAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCUS
- LILAK
- Stock Information
- Founded
- RCUS 2015
- LILAK 2017
- Country
- RCUS United States
- LILAK Bermuda
- Employees
- RCUS N/A
- LILAK N/A
- Industry
- RCUS Biotechnology: Pharmaceutical Preparations
- LILAK Cable & Other Pay Television Services
- Sector
- RCUS Health Care
- LILAK Telecommunications
- Exchange
- RCUS Nasdaq
- LILAK Nasdaq
- Market Cap
- RCUS 906.4M
- LILAK 1.1B
- IPO Year
- RCUS 2018
- LILAK N/A
- Fundamental
- Price
- RCUS $8.92
- LILAK $5.00
- Analyst Decision
- RCUS Buy
- LILAK Buy
- Analyst Count
- RCUS 11
- LILAK 3
- Target Price
- RCUS $25.33
- LILAK $10.27
- AVG Volume (30 Days)
- RCUS 1.2M
- LILAK 1.8M
- Earning Date
- RCUS 05-06-2025
- LILAK 05-07-2025
- Dividend Yield
- RCUS N/A
- LILAK N/A
- EPS Growth
- RCUS N/A
- LILAK N/A
- EPS
- RCUS N/A
- LILAK N/A
- Revenue
- RCUS $141,000,000.00
- LILAK $4,441,000,000.00
- Revenue This Year
- RCUS N/A
- LILAK $3.30
- Revenue Next Year
- RCUS $29.83
- LILAK $3.11
- P/E Ratio
- RCUS N/A
- LILAK N/A
- Revenue Growth
- RCUS N/A
- LILAK N/A
- 52 Week Low
- RCUS $6.50
- LILAK $4.23
- 52 Week High
- RCUS $18.98
- LILAK $10.93
- Technical
- Relative Strength Index (RSI)
- RCUS 53.03
- LILAK 43.03
- Support Level
- RCUS $8.42
- LILAK $4.93
- Resistance Level
- RCUS $9.61
- LILAK $5.30
- Average True Range (ATR)
- RCUS 0.49
- LILAK 0.25
- MACD
- RCUS 0.06
- LILAK 0.02
- Stochastic Oscillator
- RCUS 48.89
- LILAK 55.17
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
About LILAK Liberty Latin America Ltd. Class C
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.